Fig. 4

Association of the risk score with immunological subtypes and indicators associated with immunotherapy. (A) Association of risk score with CD8 + cell effector genes. (B) Association of risk score with TLS. (C) Relationship of risk score with 10 inhibitory immune checkpoints, including TIGIT, IDO1, PD-1, LAG-3, CTLA-4, PD-L1, and TIM-3. (D) Heatmap plot demonstrated enrichment of hot tumor signature genes (CXCR4, CXCL10, CXCL9, CD4, CXCR3, CD3E, CD8B, CXCL11, PDCD1, CD274, CD8A, and CCL5) in hot tumor specimens. (E) Risk score was considerably reduced in hot tumors, demonstrating its involvement in clinical responsiveness to immunotherapeutic regimens. (F) Differences in GEP and CYT between high- and high-risk groups. (G) Differences in TCR and BCR diversity values between high- and low-risk groups. (H) Differences in the enrichment scores of most immunotherapeutic-positive gene signatures between high- and low-risk groups. (I) Differences in the tumor stemness index between high- and low-risk groups